Zacks Investment Research
20 Jul 2026, 22:51 UTC · 13w ago
Moderna (MRNA) Suffers a Larger Drop Than the General Market: Key Insights
Impact · against what's priced in
Moderna's near-term outlook is negative as the market prepares for continued quarterly losses and a double-digit decline in revenue. While there has been a marginal upward revision in EPS estimates, it is insufficient to offset the overall trend of shrinking top-line growth.
- MRNA−0.30
No priced-in read yet
- In context
The company is expected to report an EPS of -$1.97 and a 10.81% decrease in quarterly net sales to $126.65 million, signaling continued operational losses and shrinking revenue.
Read from the article alone
